MediWound, an Israeli biotechnology company, the developer of a unique medicament for the initial treatment of second and third degree burns, reports it has commenced Phase III clinical trials. This is the final phase prior to acceptance of the product’s approval for marketing in the EC. The Company expects the approval to be granted during year 2007.
